The present invention belongs to the fields of tumor treatment and molecular immunology and provides an anti-CTLA4 monoclonal antibody or an antigen binding fragment thereof, a medicinal composition thereof, and a use thereof. The monoclonal antibody of the present invention blocks CTLA4 from binding to B7, thereby eliminating the immunosuppressive effect of CTLA4 on the host and activating T lymphocytes.